Want to see COLL full AI Analyst Report?
COLL Stock Chart & Stats
$34.41
$3.70(12.70%)
At close: 4:00 PM EST
$34.41
$3.70(12.70%)
Day’s Range― - ―
52-Week Range$29.19 - $50.79
Previous CloseN/A
Volume233.62K
Average Volume (3M)422.31K
Market Cap
$1.22B
Enterprise Value$1.63B
Total Cash (Recent Filing)$421.75M
Total Debt (Recent Filing)$808.06M
Price to Earnings (P/E)15.4
Beta0.44
Next Earnings
Jul 30, 2026EPS Estimate
1.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.37
Shares Outstanding32,433,780
10 Day Avg. Volume538,255
30 Day Avg. Volume422,308
Financial Highlights & Ratios
PEG Ratio-3.13
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit3.38
Enterprise Value/Ebitda2.68
Forecast
1Y Price Target
$54.00Price Target Upside56.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)7.78
Revenue Forecast (FY)$872.90M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained operating cash flow and nearly equal free cash flow provide durable internal funding for R&D, commercial expansion, M&A and shareholder returns. This high cash conversion supports deleveraging and strategic flexibility even when financing M&A or undertaking multi-year marketing investments.
JORNAY Commercial MomentumRapid prescription growth, rising prescriber counts and expanding market share signal durable product adoption and brand differentiation in long‑acting methylphenidate. A growing, repeat-prescription base and strong HCP intent underpin predictable revenue and a scalable commercial model for the ADHD franchise.
Strategic AZSTARYS AcquisitionAcquiring a patent-protected ADHD asset extends the company into a complimentary CNS category, diversifies revenue beyond pain, and is likely to be immediately accretive. Patent longevity plus targeted cost synergies create multi-year revenue visibility and margin upside when integration targets are met.
Bears Say
Elevated LeverageHigh absolute debt and a leverage ratio above industry best-in-class constrain financial flexibility, increase refinancing risk and limit the company's ability to fund opportunistic investments. Deleveraging depends on continued cash generation and successful integration of acquisitions.
Rising Commercial ExpensesDeliberate investments in sales and marketing to support ADHD growth raise recurring cost base. If revenue ramps slower than planned, these higher fixed commercial costs could compress margins and slow free cash flow growth, making sustained profitability contingent on successful market penetration.
Generic Risk To Legacy FranchiseAuthorized/generic entrants on legacy opioid brands create structural downside for volume and pricing over the long term. Continued generic pressure can erode a material portion of established cash flows, increasing reliance on newer ADHD assets to sustain growth and margins.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical Inc.’s price range in the past 12 months?
Collegium Pharmaceutical Inc. lowest stock price was $29.19 and its highest was $50.79 in the past 12 months.
What is Collegium Pharmaceutical Inc.’s market cap?
Collegium Pharmaceutical Inc.’s market cap is $1.22B.
When is Collegium Pharmaceutical Inc.’s upcoming earnings report date?
Collegium Pharmaceutical Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 22 days.
How were Collegium Pharmaceutical Inc.’s earnings last quarter?
Collegium Pharmaceutical Inc. released its earnings results on May 07, 2026. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.524 by $0.236.
Is Collegium Pharmaceutical Inc. overvalued?
According to Wall Street analysts Collegium Pharmaceutical Inc.’s price is currently Undervalued.
Does Collegium Pharmaceutical Inc. pay dividends?
Collegium Pharmaceutical Inc. does not currently pay dividends.
What is Collegium Pharmaceutical Inc.’s EPS estimate?
Collegium Pharmaceutical Inc.’s EPS estimate is 1.73.
How many shares outstanding does Collegium Pharmaceutical Inc. have?
Collegium Pharmaceutical Inc. has 32,433,780 shares outstanding.
What happened to Collegium Pharmaceutical Inc.’s price movement after its last earnings report?
Collegium Pharmaceutical Inc. reported an EPS of $1.76 in its last earnings report, beating expectations of $1.524. Following the earnings report the stock price went up 7.724%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in COLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (56.93% Upside)
$54.00 (56.93% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 81.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $628.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.45%
12-Months-Change
Fundamentals
Return on Equity
26.74%
Trailing 12-Months
Asset Growth
1.26%
Trailing 12-Months
Company Description
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
COLL Company Deck
COLL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple clear commercial and financial positives: robust JORNAY prescription and revenue momentum, a durable pain portfolio, strong cash generation, and a strategic, accretive acquisition (AZSTARYS) that extends portfolio longevity and is expected to add revenue and synergies. Noted headwinds include higher operating expenses from deliberate commercial investments, generic/authorized generic dynamics for Nucynta, seasonal script pressure, and a temporary increase in leverage to fund the acquisition. Overall the company presented growth initiatives with supporting data and a plan to manage risks, and management reaffirmed guidance while outlining accretion and synergies from AZSTARYS.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$54.00
▲(56.93% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
12.97% Insiders
30.66% Mutual Funds
0.25% Other Institutional Investors
25.21% Public Companies and
Individual Investors